AG真人官方

Moody鈥檚 Corp. (MCO) 鈥� Form 4 filed 4 Aug 2025

President & CEO Robert Fauber executed routine option exercises and a modest share sale under a Rule 10b5-1 plan adopted 30 Jul 2024.

• Options exercised: 56 sh @ $80.81, 134 sh @ $94.18, 91 sh @ $113.34 (total 281 sh).
• Sale: 415 common shares sold @ $510.19.
• Net change: 鈭�134 shares; direct holding now 61,751.984 shares.
• Residual options: 7,921 unexercised across the three grants.

The sale equates to roughly 0.2 % of Fauber鈥檚 direct stake and does not materially alter insider ownership levels or signal a strategic shift. No operational or financial guidance is affected.

Jaguar Health (JAGX) has filed a Form S-3 to register up to 1,409,732 common shares for resale by existing investors. The stock derives from (i) 481,150 shares underlying 6 % convertible Replacement Notes issued 24 Jun 2025 (conversion price $5.535鈥�$5.555, maturity 30 Jan 2026) and (ii) 928,582 shares issuable on cash or cash-less exercise of accompanying warrants (exercise price $2.70, 18-month term). At the 23 Jul 2025 close of $2.38 the warrant strikes sit 13 % above market while the note conversion price is >130 % above market. If fully converted/exercised the new shares would expand the current 1.914 million share float by roughly 74 %, creating a sizeable overhang.

The company will not receive proceeds from secondary sales; only a full cash exercise of all warrants could raise ~$2.5 million, earmarked for working capital. The filing follows several recent financings (March convertible notes and May registered direct offering) and occurs alongside an active GI-focused drug pipeline led by crofelemer (FDA-approved Mytesi, multiple Phase 2/3 programs, orphan designations) and the October 2024 U.S. launch of Gelclair for oral mucositis. While pipeline breadth offers optionality, near-term investors must weigh dilution risk and potential price pressure from selling stockholders against the modest capital infusion possible from warrant exercises.

BTC Digital Ltd. (Nasdaq: BTCT) has filed a preliminary prospectus supplement for a direct offering of ordinary shares and pre-funded warrants to unnamed institutional investors. Aegis Capital Corp. will act as placement agent on a best-efforts basis and will receive a 7.0 % cash fee plus expense reimbursement. Key economic terms鈥攊ncluding the number of shares, warrant count, and offering price鈥攁re still bracketed and subject to finalisation.

The pre-funded warrants carry a de minimis exercise price of US$0.00001 per share, are exercisable immediately, and feature customary anti-dilution protections. All directors, officers and 10 % shareholders will enter 90-day lock-ups, and the company itself is subject to the same stand-still period for new equity issuance (with limited exceptions). Closing is targeted for 16 July 2025, subject to customary conditions.

Use of proceeds: net proceeds are earmarked for the purchase of Ethereum, indicating an intention to diversify beyond the company鈥檚 core bitcoin-mining focus. Management highlights prior takedowns under the same shelf (US$8.87 m in shares and US$12.95 m in pre-funded warrants sold in December 2024).

Business snapshot: BTC Digital is a Cayman-incorporated crypto-asset technology company with operations in the United States. Revenue for FY-2024 was 鈥渟ubstantially鈥� derived from bitcoin mining and mining-machine resale. Counsel confirms the transaction does not trigger PRC CSRC filing requirements.

Risk considerations flagged include crypto-market volatility, use-of-proceeds concentration in Ethereum, potential dilution, and general crypto regulatory uncertainty. All quantitative dilution, capitalization and pricing tables remain incomplete pending final terms.

Quanterix Corporation (QTRX) filed Post-Effective Amendment No. 3 on Form S-8 to its previously declared-effective Form S-4, completing the technical step needed to register shares that will be issued under equity awards assumed from Akoya Biosciences following the recently closed merger.

• Shares registered: 253,181 shares of Quanterix common stock, representing the maximum issuable upon vesting of outstanding Akoya restricted stock units ("Rollover RSUs").
• Merger exchange ratio: each Akoya share converted at closing into 0.1470 Quanterix share plus $0.37 cash.
• Total shares previously registered: 8,357,169 on the original Form S-4, covering stock consideration to Akoya shareholders and all equity awards; today鈥檚 filing carves out only the RSU component.
• Fees: all SEC filing fees were paid with the original Form S-4; no additional fees are due.
• Plan coverage: the amendment relates to the Akoya Biosciences 2015 & 2021 Equity Incentive Plans, now assumed by Quanterix.
• Rule 416(a) applicability: automatic coverage for share increases from stock splits, dividends, or similar corporate actions.

Part II of the filing reiterates standard incorporation by reference of recent Quanterix periodic reports, describes Delaware law-based indemnification provisions, and lists exhibits, including opinions from Covington & Burling LLP and auditor consents. The document is strictly administrative鈥攏o new financial results, guidance, or strategic changes are disclosed; its primary purpose is to ensure that shares underlying assumed Akoya equity awards are properly registered for issuance post-merger.

Stardust Power Inc. (NASDAQ: SDST/SDSTW) has filed Amendment No. 1 to its Form 10-K for the fiscal year ended 31 December 2024. The sole purpose of the 10-K/A is to replace Item 9A 鈥淐ontrols and Procedures,鈥� which was inadvertently omitted in the original 27 March 2025 filing. No other sections, including the consolidated financial statements, have been revised.

Key disclosures now provided:

• Disclosure Controls & Procedures: CEO and CFO evaluated the design and operation of disclosure controls as of 31 December 2024 and concluded they were effective.
• Internal Control over Financial Reporting (ICFR): Using the 2013 COSO framework, management assessed ICFR as effective at year-end 2024; there were no material weaknesses outstanding at that date.
• Material-weakness remediation: Weaknesses identified for the 16 Mar 2023鈥�31 Dec 2023 inception period (segregation of duties, contract repository, complex instruments, COSO components) were fully remediated during 2024.
• Emerging Growth Company (EGC): As an EGC, the company is exempt from auditor attestation of ICFR under the JOBS Act.
• Capitalisation snapshot: 84,447,421 common shares outstanding (10 Jul 2025); public float market value of US$38.7 million as of 31 Dec 2024.

The filing re-affirms that there were no changes in ICFR during the last fiscal quarter other than the stated remediation efforts, and that inherent limitations of internal controls persist. All certificates (CEO/CFO, XBRL exhibits) are included with the amendment.

Form 4 overview: On 07/10/2025, director Matthew Winkler reported the automatic disposition of 984,513 Akoya Biosciences (AKYA) common shares on 07/08/2025 under transaction code J. The shares were converted pursuant to the Amended and Restated Agreement and Plan of Merger dated 04/28/2025, whereby Akoya merged with a wholly owned subsidiary of Quanterix Corporation and became its wholly owned subsidiary.

Under the merger terms, each Akoya share was exchanged for 0.1461 Quanterix share plus $0.38 in cash, subject to potential adjustment. Following the closing, Winkler now reports zero AKYA shares beneficially owned.

The filing also discloses the cancellation of 153,731 stock options with strike prices between $2.01 and $21.95 that were at or above the per-share merger consideration; these options were terminated for no consideration.

No open-market trades, pricing data, or new financial metrics are included鈥攖his is a procedural disclosure linked solely to the completed merger.